Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
study ends around

Description

Summary

The purpose of this study is to determine whether the combination therapy of CC-486 (oral azacitidine) and pembrolizumab provides improved patient outcomes compared to pembrolizumab alone in patients with previously treated locally advanced or metastatic non-small cell lung cancer.

Official Title

A Phase 2 Multicenter, Randomized, Placebo Controlled, Double Blind Study to Assess the Safety and Efficacy of CC-486 (Oral Azacitidine) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo in Subjects With Previously Treated Locally Advanced or Metastatic Non-small Cell Lung Cancer

Details

Keywords

Carcinoma, Non-Small-Cell Lung, CC-486, Azacitidine, Oral azacitidine, Methyltransferase inhibitor, Hypomethylation, Hypomethylating agent, Epigenetic, MK-3475, Pembrolizumab, Keytruda, PD-1, PD-L1, ImmunotherapyAdvanced non-small cell lung cancer, Metastatic non-small cell lung cancer, Non-small cell lung cancer, NSCLC, Merck Pembrolizumab (Keynote-117), Lung Neoplasms, Non-Small-Cell Lung Carcinoma, CC-486 plus Pembrolizumab

Eligibility

Locations

  • UCLA Hematology Oncology
    Los Angeles California 90095 United States
  • Palo Verde Hematology Oncology
    Glendale Arizona 85304 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Celgene
Links
BMS Clinical Trial Information
ID
NCT02546986
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 100 people participating
Last Updated